Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment

Author:

Loo Kimberly12ORCID,Kalvin Hannah L3,Panageas Katherine S3,Park Vivian4,Postow Michael A15

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA

2. Department of Internal Medicine, New York-Presbyterian Hospital and Weill Cornell Medicine , New York, NY , USA

3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY , USA

4. Division of Pharmacy Services, Memorial Sloan Kettering Cancer Center , New York, NY , USA

5. Weill Cornell Medical College , New York, NY , USA

Abstract

Abstract Background Little is known about patient outcomes with advanced melanoma following inpatient initiation or continuation of immune checkpoint blockade (ICB). Methods and Results We conducted a single institution retrospective case series of advanced melanoma patients who initiated ICB as an inpatient (initial inpatient cohort, n = 9), or continued ICB as an inpatient after previously starting as an outpatient (outpatient then inpatient cohort, n = 5). One patient had a partial response to ICB initiated as an inpatient, but ultimately died of melanoma after 13.5 months. Median overall survival for initial inpatient cohort was 1.0 month (95% CI: 0.2-11.2), and 1.4 months (95% CI: 0.4-58.0) for the outpatient then inpatient cohort. Three patients were alive >6 months after inpatient ICB administration. Conclusion Despite overall poor outcomes, some patients may benefit from inpatient ICB. This study provides additional information for clinicians to appropriately counsel patients on expectations following inpatient ICB.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3